scholarly journals Metronidazole induced peripheral neuropathy

1970 ◽  
Vol 9 (2) ◽  
pp. 119-121 ◽  
Author(s):  
R Maskey ◽  
SK Sharma ◽  
KN Poudel
Keyword(s):  
Peripheral Neuropathy ◽  
Axonal Neuropathy ◽  
Drug Induced ◽  
Electrophysiologic Test ◽  
Hepatic Amebiasis

Metronidazole is a little known cause of drug-induced neuropathy.We report a patient who developed paraesthesia of both limbs after one month course of metronidazole. The electrophysiologic test confirmed a bilateral motor-axonal neuropathy. This neuropathy improved dramatically with cessation of the drug. Keywords: metronidazole; peripheral neuropathy; hepatic amebiasis DOI: http://dx.doi.org/10.3126/hren.v9i2.4986 Health Renaissance 2011: Vol.9 (No.2): 119-121

scholarly journals Genome-Wide Screen Identifies Drug-Induced Regulation of the Gene Giant Axonal Neuropathy (Gan) in a Mouse Model of Antiretroviral-Induced Painful Peripheral Neuropathy

2009 ◽  
Vol 11 (1) ◽  
pp. 7-16 ◽  
Author(s):  
Susan G. Dorsey ◽  
Carmen C. Leitch ◽  
Cynthia L. Renn ◽  
Sherrie Lessans ◽  
Barbara A. Smith ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Mouse Model ◽  
Side Effect ◽  
Quantitative Polymerase Chain Reaction ◽  
Axonal Neuropathy ◽  
Protein Product ◽  
Hiv Treatment ◽  
Patient Comfort ◽  
Giant Axonal Neuropathy ◽  
Drug Induced

Painful peripheral neuropathy is a debilitating complication of the treatment of HIV with nucleoside reverse transcriptase inhibitors (NRTIs). Patients are living longer with these drugs; however many develop excruciating, unremitting, and often treatment-limiting neuropathy that is resistant to conventional pain management therapies. Improving patient comfort and quality of life is paramount and depends on a clearer understanding of this devastating side effect. The mechanisms underlying the development of NRTI-induced neuropathy, however, remain unclear. Using a mouse model of NRTI-induced neuropathy, the authors conducted an unbiased whole-genome microarray screen to identify molecular targets in the spinal dorsal horn, which is the location where integration of ascending sensory transmission and descending modulatory effects occur. Analysis of the microarray data identified a change in the gene giant axonal neuropathy 1 (Gan1). Mutation of this gene has been linked to the development of giant axonal neuropathy (GAN), a rare autosomal recessive condition characterized by a progressive sensorimotor neuropathy. Gan1 has not been previously linked to nerve pathologies in other populations. In this study, downregulation of the Gan1 gene and the gene protein product, gigaxonin, was validated via quantitative polymerase chain reaction ([qPCR] gene expression) and Western blot analyses (protein level). Our report is the first to suggest that Gan1 might be a novel molecular target in the development of NRTI-induced peripheral neuropathy with implications for new therapeutic approaches to preventing or reducing a significant side effect of HIV treatment.

Drug-Induced Peripheral Neuropathy: Diagnosis and Management

2021 ◽  
Vol 21 ◽  
Author(s):  
Diala Merheb ◽  
Georgette Dib ◽  
Maroun Bou Zerdan ◽  
Clara El Nakib ◽  
Saada Alame ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Systematic Approach ◽  
Viral Infections ◽  
Cost Effective ◽  
Nerve Fibers ◽  
Drug Induced ◽  
Vitamin Deficiencies ◽  
Effective Diagnosis ◽  
Different Parts ◽  
Pathophysiologic Mechanisms

: Peripheral neuropathy comes in all shapes and forms and is a disorder which is found in the peripheral nervous system. It can have an acute or chronic onset depending on the multitude of pathophysiologic mechanisms involving different parts of nerve fibers. A systematic approach is highly beneficial when it comes to cost-effective diagnosis. More than 30 causes of peripheral neuropathy exist ranging from systemic and auto-immune diseases, vitamin deficiencies, viral infections, diabetes, etc. One of the major causes of peripheral neuropathy is drug induced disease, which can be split into peripheral neuropathy caused by chemotherapy or by other medications. This review deals with the latest causes of drug induced peripheral neuropathy, the population involved, the findings on physical examination and various workups needed and how to manage each case.

Prevention and Management of Drug-Induced Peripheral Neuropathy

Drug Safety ◽  
1991 ◽  
Vol 6 (4) ◽  
pp. 302-314 ◽  
Author(s):  
Line Lisbeth Olesen ◽  
Troels Staehelin Jensen
Keyword(s):  
Peripheral Neuropathy ◽  
Drug Induced

Utilization of iPSC-derived human neurons for high-throughput drug-induced peripheral neuropathy screening

2017 ◽  
Vol 45 ◽  
pp. 111-118 ◽  
Author(s):  
Payal Rana ◽  
Gregory Luerman ◽  
Dietmar Hess ◽  
Elizabeth Rubitski ◽  
Karissa Adkins ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
High Throughput ◽  
Drug Induced ◽  
Human Neurons

scholarly journals Pattern of Peripheral Neuropathy and B12 Assay among Type 2 Diabetic Saudi Patients

2020 ◽  
Vol 5 (11) ◽  
pp. 529-532
Author(s):  
Ahmed Abdulrahaman Ghalib ◽  
Jamil Ramadan ◽  
Bothaina Omar Marae
Keyword(s):  
Peripheral Neuropathy ◽  
Carpal Tunnel Syndrome ◽  
Glycemic Control ◽  
Vitamin B12 ◽  
Carpal Tunnel ◽  
Nerve Conduction Study ◽  
Nerve Conduction ◽  
Axonal Neuropathy ◽  
Hypoglycemic Agents ◽  
Tunnel Syndrome

Objectives: to determine whether the pattern of peripheral neuropathy among Saudi types 2 diabetics has association with B12 status and glycemic control. Method: A cross section hospital based study. The pattern of diabetic neuropathy was determined by nerve conductive velocity (NCV) test, level of vitamin b12 was assayed among the study population and the glycemic control was determined according to Hba1c level. Results: A total of thirty three patients were enrolled in these study twenty one females and twelve males. The age ranged between 79 and 34 with the mean (SD) of 57 of these 17 (51.5%) used oral hypoglycemic agents and 16 (48.5%) were using insulin. HbAc1 more than 7 was found in 28 (84.8%) of the patients reflecting poor control. The nerve conduction study testing revealed that sensory axonal demyelination 6(18.2%), bilateral neuropathy 8 (24.2%), Right Carpal tunnel syndrome 5(15.2%), Left Carpal tunnel syndrome 0 (00%), mild axonal neuropathy 4 (12.1%) and 10 (30.3%) were found to have normal nerve conduction study test. The level of vitamin B12 was found 2(6%) was deficiency <180 pg/ml, 12(36.3%) possible deficiency 212 pg/ml-350 pg/ml and 19(57.5%) was >400 pg/ml. Conclusion: It could be concluded from this study that there is no association between pattern of peripheral neuropathy and B12 level in type II diabetics. Similarly no relation exists between Hb Ac1 level and pattern of peripheral neuropathy.

scholarly journals Drug-Induced Peripheral Neuropathy: A Narrative Review

2020 ◽  
Vol 15 (1) ◽  
pp. 38-48 ◽  
Author(s):  
Mark R. Jones ◽  
Ivan Urits ◽  
John Wolf ◽  
Devin Corrigan ◽  
Luc Colburn ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Treatment Options ◽  
Chemotherapeutic Agents ◽  
Research Literature ◽  
Cardiovascular Drugs ◽  
Bibliographic Databases ◽  
Drug Induced ◽  
Painful Condition ◽  
Review Question ◽  
New Onset

Background: Peripheral neuropathy is a painful condition deriving from many and varied etiologies. Certain medications have been implicated in the iatrogenic development of Drug Induced Peripheral Neuropathy (DIPN) and include chemotherapeutic agents, antimicrobials, cardiovascular drugs, psychotropic, anticonvulsants, among others. This review synthesizes current clinical concepts regarding the mechanism, common inciting medications, and treatment options for drug-induced peripheral neuropathy. Methods: The authors undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question and inclusion/exclusion criteria. The most relevant and up to date research was included. Results: Drug-induced peripheral neuropathy is a common and painful condition caused by many different and frequently prescribed medications. Most often, DIPN is seen in chemotherapeutic agents, antimicrobials, cardiovascular drugs, psychotropic, and anticonvulsant drugs. Certain drugs exhibit more consistent neuropathic side effects, such as the chemotherapeutic compounds, but others are more commonly prescribed by a larger proportion of providers, such as the statins. DIPN is more likely to occur in patients with concomitant risk factors such as preexisting neuropathy, diabetes, and associated genetically predisposing diseases. DIPN is often difficult to treat, however medications including duloxetine, and gabapentin are shown to reduce neuropathic pain. Advanced techniques of neuromodulation offer promise though further randomized and controlled studies are needed to confirm efficacy. Conclusion: Awareness of the drugs covered in this review and their potential for adverse neuropathic effect is important for providers caring for patients who report new onset symptoms of pain, paresthesia, or weakness. Prevention of DIPN is especially important because treatment often proves challenging. While many pharmacologic therapies have demonstrated analgesic potential in the pain caused by DIPN, many patients remain refractive to treatment. More studies are needed to elucidate the effectiveness of interventional, neuromodulating therapies.

scholarly journals Neuropathy in the setting of alcoholism-an entity less thought of

2020 ◽  
Vol 8 (12) ◽  
pp. 4518
Author(s):  
Shasthara Paneyala ◽  
Nemichandra S. C. ◽  
Harsha Sundaramurthy ◽  
Vimala Christina Colaco K.
Keyword(s):  
Peripheral Neuropathy ◽  
Side Effect ◽  
Axonal Neuropathy ◽  
Foot Drop ◽  
Sensory Loss ◽  
Adjunctive Treatment ◽  
Alcohol Dependency ◽  
Vitamin B ◽  
Motor Power ◽  
Vitamin B 12

Disulfiram is a commonly used adjunctive treatment in the management of alcohol dependency.  It has been noted that disulfiram can induce peripheral neuropathy, the mechanism of which has not been clearly determined. A 35-year-old patient, reformed alcoholic, on disulfiram presented with complaints of painful distal dysesthesias and foot drop. Clinical examination revealed bilateral foot drop without any objective sensory loss. Patient was evaluated for the same and routine blood investigations including vitamin B-12, inflammatory and virological markers were found to be normal. Nerve conductions studies revealed in excitable bilateral common peroneal and tibial nerves. Possibility of disulfiram induced peripheral neuropathy was thought of and drug was withdrawn. Patient was followed up and after two months improvement in motor power and reduction in paraesthesia’s was noted. Disulfiram is a commonly used drug, the uncommon side effect of which is distal predominant axonal neuropathy. This must be kept be kept in mind when evaluating a patient presenting with features of peripheral neuropathy, on a background of alcohol abuse.

Sign in / Sign up

Export Citation Format

Share Document